[go: up one dir, main page]

GT200900137A - Fusiones fc con receptor para fgf soluble modificaciones, con actividad biologica mejorada. - Google Patents

Fusiones fc con receptor para fgf soluble modificaciones, con actividad biologica mejorada.

Info

Publication number
GT200900137A
GT200900137A GT200900137A GT200900137A GT200900137A GT 200900137 A GT200900137 A GT 200900137A GT 200900137 A GT200900137 A GT 200900137A GT 200900137 A GT200900137 A GT 200900137A GT 200900137 A GT200900137 A GT 200900137A
Authority
GT
Guatemala
Prior art keywords
fgf
receiver
soluble
biological activity
improved biological
Prior art date
Application number
GT200900137A
Other languages
English (en)
Inventor
Francis Blanche
Beatrice Cameron
Mark Nesbit
Celine Nicolazzi
Sylvie Sordello
Marc Trombe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39431092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200900137(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200900137A publication Critical patent/GT200900137A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE A FUSIONES FC CON RECEPTOR PARA FGF SOLUBLE, MODIFICADAS, QUE COMPRENDEN UNA FUSIÓN DE UN FRAGMENTO O DOMINIO SOLUBLES DE LA PARTE DE RECEPTOR PARA FGF (PORCIÓN QUE ESTABLECE EL OBJETIVO O FIJADORA) CON UNA REGIÓN FC DE UNA PARTE DE IMMUNOGLOBULINA (PORCIÓN CON FUNCIÓN EFECTORA), QUE TIENEN ACTIVIDAD BIOLÓGICA MEJORADA, QUE INCLUYE ACTIVIDADES DE ADCC/CDC, A COMPOSICIONES QUE LAS CONTIENEN, Y A MÉTODO DE PRODUCIR DICHAS MOLÉCULAS DE FUSIÓN FC CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS.
GT200900137A 2006-11-28 2009-05-20 Fusiones fc con receptor para fgf soluble modificaciones, con actividad biologica mejorada. GT200900137A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28
EP07290042 2007-01-11

Publications (1)

Publication Number Publication Date
GT200900137A true GT200900137A (es) 2011-09-02

Family

ID=39431092

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900137A GT200900137A (es) 2006-11-28 2009-05-20 Fusiones fc con receptor para fgf soluble modificaciones, con actividad biologica mejorada.

Country Status (33)

Country Link
US (3) US8119770B2 (es)
EP (1) EP2092069B2 (es)
JP (1) JP2010510801A (es)
KR (1) KR20090102769A (es)
AR (1) AR063975A1 (es)
AT (1) ATE509106T1 (es)
AU (1) AU2007326985C1 (es)
BR (1) BRPI0719290A2 (es)
CA (1) CA2668932A1 (es)
CL (1) CL2007003411A1 (es)
CO (1) CO6190564A2 (es)
CR (1) CR10777A (es)
CY (1) CY1112435T1 (es)
DK (1) DK2092069T3 (es)
EA (1) EA018700B1 (es)
EC (1) ECSP099361A (es)
GT (1) GT200900137A (es)
HR (1) HRP20110503T1 (es)
IL (1) IL198480A0 (es)
MA (1) MA31143B1 (es)
MX (1) MX2009005692A (es)
MY (1) MY145914A (es)
NI (1) NI200900097A (es)
NO (1) NO20092414L (es)
PE (1) PE20081250A1 (es)
PL (1) PL2092069T3 (es)
PT (1) PT2092069E (es)
RS (1) RS51911B (es)
SI (1) SI2092069T1 (es)
SV (1) SV2009003272A (es)
TN (1) TN2009000184A1 (es)
TW (1) TW200839012A (es)
WO (1) WO2008065543A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2622522T3 (es) 2003-08-26 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad proteasa de serina y su uso en métodos y composiciones para el tratamiento de infecciones bacterianas
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
PL2498799T3 (pl) 2009-11-13 2017-03-31 Five Prime Therapeutics, Inc. Zastosowanie białek domeny zewnątrzkomórkowej FGFR1 do leczenia nowotworów charakteryzujących się mutacjami aktywującymi zależnymi od ligandów w FGFR2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
JP6178240B2 (ja) * 2010-11-15 2017-08-09 ファイブ プライム セラピューティックス インコーポレイテッド 高用量の可溶性ｆｇｆｒ１融合タンパク質を用いるがんの治療
AU2015258172B2 (en) * 2010-11-15 2017-01-12 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
US20130273049A1 (en) 2010-12-23 2013-10-17 Sanofi Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CA2839917A1 (en) * 2011-06-24 2012-12-27 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
CA2855818A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression
KR20140137347A (ko) 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
SG10201809779RA (en) 2013-03-11 2018-12-28 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
BR112015029145A2 (pt) * 2013-05-23 2017-09-19 Glaxosmithkline Ip No 2 Ltd Usos de um domínio extracelular (ecd) de receptor de fator de crescimento de fibroblastos 1 (fgfr1) e métodos de identificação de pacientes
NZ715201A (en) 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
CN106471010A (zh) 2014-03-19 2017-03-01 建新公司 靶向模块的位点特异性糖工程化
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
EP3380523A1 (en) * 2015-11-23 2018-10-03 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
EP4650004A2 (en) 2017-05-16 2025-11-19 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
KR20190065234A (ko) * 2017-11-30 2019-06-11 그리폴스 다이어그노스틱 솔루션즈 인크. 면역 관문 억제제인 pd-1 및 pd-l1에 대한 항체 치료를 모니터링하기 위한 면역분석 및 조작된 단백질
WO2019136316A1 (en) * 2018-01-04 2019-07-11 Washington University Compositions and methods for inhibition of alphavirus infection
AU2019212709A1 (en) * 2018-01-26 2020-08-13 Genentech, Inc. IL-22 Fc fusion proteins and methods of use
MA55529A (fr) 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288856A (en) 1986-11-20 1994-02-22 Pierre Amiguet Method of isolating acid-stable, biologically active proteins
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5153310A (en) * 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
WO1991000916A2 (en) * 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
ATE131175T1 (de) * 1990-04-27 1995-12-15 Takeda Chemical Industries Ltd Protein mit fibroblasten-wachstumsfaktor- rezeptoraktivität.
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
EP0538404B1 (en) 1990-07-06 2003-06-18 Rhone-Poulenc Rorer International (Holdings) Inc. Fibroblast growth factor receptors
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US6612152B2 (en) * 1999-05-01 2003-09-02 James E. Keaton Lifting, servicing, and diagnosing automobiles
US6656738B1 (en) * 1999-11-17 2003-12-02 Bae Systems Integrated Defense Solutions Inc. Internal heater for preconcentrator
WO2002002597A2 (en) * 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
HU231090B1 (hu) * 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
CA2481837A1 (en) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
WO2003085119A1 (en) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
AU2004265226A1 (en) 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
AU2004280066A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell
DE102004022895A1 (de) 2004-05-10 2005-12-08 Adam Opel Ag Schallabsorbierendes Verkleidungselement
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties

Also Published As

Publication number Publication date
MA31143B1 (fr) 2010-02-01
US20120195851A1 (en) 2012-08-02
NI200900097A (es) 2010-01-26
WO2008065543A2 (en) 2008-06-05
CY1112435T1 (el) 2015-12-09
AU2007326985B2 (en) 2013-08-15
US20100061979A1 (en) 2010-03-11
CA2668932A1 (en) 2008-06-05
SI2092069T1 (sl) 2011-09-30
HRP20110503T1 (hr) 2011-08-31
CR10777A (es) 2009-07-23
PL2092069T3 (pl) 2011-10-31
EP2092069B2 (en) 2013-12-18
EA018700B1 (ru) 2013-10-30
WO2008065543A3 (en) 2008-08-14
TN2009000184A1 (en) 2010-10-18
US20140030265A1 (en) 2014-01-30
EP2092069B1 (en) 2011-05-11
KR20090102769A (ko) 2009-09-30
AU2007326985C1 (en) 2014-02-20
RS51911B (sr) 2012-02-29
MX2009005692A (es) 2009-10-12
IL198480A0 (en) 2011-08-01
AU2007326985A1 (en) 2008-06-05
BRPI0719290A2 (pt) 2014-02-25
JP2010510801A (ja) 2010-04-08
US8481487B2 (en) 2013-07-09
EP2092069A2 (en) 2009-08-26
PE20081250A1 (es) 2008-10-07
SV2009003272A (es) 2010-02-05
CO6190564A2 (es) 2010-08-19
PT2092069E (pt) 2011-07-29
NO20092414L (no) 2009-08-21
ATE509106T1 (de) 2011-05-15
CL2007003411A1 (es) 2008-07-04
EA200970515A1 (ru) 2009-12-30
DK2092069T3 (da) 2011-08-29
AR063975A1 (es) 2009-03-04
ECSP099361A (es) 2009-06-30
TW200839012A (en) 2008-10-01
US8119770B2 (en) 2012-02-21
MY145914A (en) 2012-05-15

Similar Documents

Publication Publication Date Title
GT200900137A (es) Fusiones fc con receptor para fgf soluble modificaciones, con actividad biologica mejorada.
BR112022010206A2 (pt) Receptores de antígeno quiméricos e usos dos mesmos
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
PE20081478A1 (es) Anticuerpos cd44
CR20110496A (es) Biespecificos anticuerpos anti-her
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
DK2073842T3 (da) Anvendelse af humane celler af myeloid leukæmioprindelse til ekspression af antistoffer.
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
WO2016081746A3 (en) Antibodies comprising modified heavy constant regions
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
CY1118797T1 (el) Ανταγωνιστες toll-ωδους υποδοχεα 3
EP1824872A4 (en) RNAI MODULATION OF MLL-AF4 AND USES THEREOF
WO2009112245A9 (en) Antibody against the csf-1 r
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
NO20080246L (no) Anti-IGF1R-antistofformuleringer
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
ECSP066559A (es)
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
ATE431824T1 (de) Chinolinon-carboxamid-verbindungen
WO2010045229A3 (en) Protecting and repairing cartilage and musculoskeletal soft tissues
UY30749A1 (es) Fusiones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada
NO20073369L (no) Modulatorer av muskarinreseptorer